Illumina Inc ILMN:NASDAQ

Last Price$280.47Cboe Real-Time Last Sale as of 1:25PM ET 8/23/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-8.11(2.81%)
Bid (Size)$280.65 (19)
Ask (Size)$280.95 (100)
Day Low / High$280.91 - 289.44
Volume450.0 K
 

View Biotechnology IndustryPeer Comparison as of 08/23/2019

 

Illumina Inc ( NASDAQ )

Price: $280.47
Change: -8.11 (2.81%)
Volume: 450.0 K
1:25PM ET 8/23/2019
 
 

Biogen Inc ( NASDAQ )

Price: $227.89
Change: -4.17 (1.80%)
Volume: 412.6 K
1:26PM ET 8/23/2019
 
 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $181.40
Change: -2.84 (1.54%)
Volume: 402.7 K
1:26PM ET 8/23/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $289.26
Change: -5.76 (1.95%)
Volume: 376.4 K
1:26PM ET 8/23/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

Insider Trends: Illumina Insider Continues 90-Day Selling Trend
6:32PM ET 8/15/2019 MT Newswires

Jay T Flatley, Director, reported a sale of 3,300 shares in Illumina (ILMN) on Aug 14, 2019, for $951,588. Following the Form 4 filing with the SEC,...

Insider Trends: Insider Sales Continue 90-Day Trend at Illumina
4:12PM ET 8/13/2019 MT Newswires

Omead Ostadan, SVP Mktg, Prod & Strat Plan, sold 1,260 shares of Illumina (ILMN) on Aug 09, 2019, for $376,160. Ostadan, subsequent to the transactions...

Insider Trends: 90-Day Insider Selling Trend Prolonged at Illumina
5:25PM ET 8/12/2019 MT Newswires

Robert P Ragusa, SVP, Global Quality & Ops, on Aug 08, 2019, sold 2,230 shares in Illumina (ILMN) for $653,591. Ragusa, subsequent to the transactions...

Insider Trends: Illumina Insider Extends 90-Day Selling Trend
4:48PM ET 8/05/2019 MT Newswires

Francis A deSouza, Director and President & CEO, on Aug 01, 2019, sold 3,000 shares in Illumina (ILMN) for $903,759. Subsequent to the Form 4 filing with...

Company Profile

Business DescriptionIllumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Phone+1.858.202.4500
Number of Employees7,300
Recent SEC Filing08/19/20194
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Technology Officer & Senior Vice PresidentMostafa Ronaghi

Company Highlights

Price Open$288.94
Previous Close$288.58
52 Week Range$268.62 - 380.76
Market Capitalization$41.2 B
Shares Outstanding147.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings45.42
Earnings per Share$5.72
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin27.56%
Return on Equity24.09%

Analyst Ratings as of 07/30/2019

Buy
9
Overweight
2
Hold
5
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset